Eli Lilly (LLY) Cost of Revenue (2009 - 2026)

Eli Lilly has reported Cost of Revenue for 18 years, with the latest figure at $3.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 60.76% year-over-year to $3.6 billion; the trailing twelve-month figure through Mar 2026 stood at $12.4 billion (up 38.3% YoY), and the FY2025 full-year result was $11.1 billion, up 31.29% from the prior year.
• Cost of Revenue for Q1 2026 stood at $3.6 billion, up from $3.4 billion in the prior quarter.
• The five-year high for Cost of Revenue was $3.6 billion in Q1 2026, with the low at $1.4 billion in Q2 2022.
• Historically, Cost of Revenue has averaged $2.2 billion across 5 years, with a median of $2.1 billion in 2022.
• Annual changes were most pronounced in 2022 — Cost of Revenue declined 26.76% — and 2026, when it soared 60.76%.
• Eli Lilly's Cost of Revenue stood at $1.5 billion in 2022, then gained by 15.48% to $1.8 billion in 2023, then soared by 34.44% to $2.4 billion in 2024, then jumped by 40.28% to $3.4 billion in 2025, then grew by 6.09% to $3.6 billion in 2026.
• The last three Cost of Revenue figures came in at $3.6 billion (Q1 2026), $3.4 billion (Q4 2025), and $3.0 billion (Q3 2025), per Business Quant data.